Сенильный аортальный стеноз: современное состояние проблемы (к 110-летию публикации И.Г.Менкеберга)

1. Бабанин В.С. Кальцификация клапанных структур сердца и факторы риска сердечно-сосудистых осложнений у женщин в постменопаузе. Дис. … канд. мед. наук. 2011.
2. Берестовая Н.А., Мосесова Н.С. Минеральная плотность костной ткани у пациентов с кальцинозом аортального клапана. Проблемы остеологии. Науч.-практ. журн. 2006; 9: 26–7.
3. Дземешкевич С.Л. Аортальные пороки в современной кардиологии. Болезни сердца и сосудов. 2006; 1: 32–3.
4. Егоров И.В., Шостак Н.А. Дегенеративный аортальный стеноз: современный взгляд на старую проблему. Клин. геронтология. 2000; 11–12: 37–42.
5. Егоров И.В. Сенильный аортальный стеноз. Лекция для врачей. Кардиология. 2001; 41 (5): 89–93.
6. Егоров И.В. Патогенетические аспекты сенильного аортального стеноза. Рос. мед. журн. 2003; 3: 48–52.
7. Егоров И.В. Сенильный аортальный стеноз – век изучения (к 100-летию публикации И.Менкеберга). Клин. медицина. 2004; 12: 69–74.
8. Егоров И.В. История изучения сенильного аортального стеноза (к 100-летию публикации И.Менкеберга). Терапевт. арх. 2004; 8: 90–3.
9. Егоров И.В. Клинико-диагностические аспекты «старческого» аортального стеноза. Проблемы женского здоровья. 2008; 2 (3): 76–9.
10. Егоров И.В. Вторичный кальциноз внутрисердечных структур. Практикующий врач. 2010; 1: 13–20.
11. Егоров И.В. Сенильный аортальный стеноз и внутрисердечный кальциноз. М.: ГЭОТАР-Медиа, 2012.
12. Кушаковский М.С., Балябин А.А. О дегенеративном (невоспалительном) кальцинированном стенозе устья аорты и его отличиях от ревматического кальцинированного стеноза устья аорты. Кардиология. 1991; 1: 56–60.
13. Митрофанова Л.Б. Клинико-морфологические особенности сердца при клапанных пороках различной этиологии. Дис. … д-ра мед. наук. 2005.
14. Преображенский Д.В., Сидоренко Б.А., Батыралиев Т.А. Ингибиторы ангиотензинпревращающего фермента. М., 2007.
15. Серговенцев А.А. Особенности клинико-лабораторных показателей у больных сенильным аортальным стенозом с сопутствующим алиментарно-конституциональным ожирением. Амбулаторная хирургия: стационарозамещающие технологии. 2005; 4: 109–10.
16. Серговенцев А.А. Течение сенильного аортального стеноза у больных с ожирением. Дис. … канд. мед. наук. 2006.
17. Серговенцев А.А. Кальцинированный аортальный стеноз: итоги 15-летнего изучения в России. Рус. мед. журн. 2013; 27: 1314–9.
18. Agmon Y, Khandheria BK, Meissner I et al. Aortic valve sclerosis and aortic atherosclerosis: different manifestations of the same disease? Insights from a population-based study. J Am Coll Cardiol 2001; 38: 827–34.
19. Alexopoulos A, Bravou V, Peroukides S et al. Bone regulatory factors NFATc1 and Osterix in human calcific aortic valves. Int J Cardiol 2010; 4 (139) [2]: 142–9.
20. Aronow WS, Schwartz KS, Koenigsberg M. Correlation of serum lipids, calcium, and phosphorus, diabetes mellitus and history of systemic hypertension with presence or absence of calcified or thickened aortic cusps or root in elderly patients. Am J Cardiol 1987; 59: 998–9.
21. Aronow WS, Ahn C, Shirani J. Comparison of frequency of new coronary events in older subjects with and without valvular aortic sclerosis. Am J Cardiol 1999; 83: 599–600.
22. Arumugam SB, Sankar NM, Cherian KM. Osseous metaplasia with functioning marrow in a calcified aortic valve. J Cardiol Surg 1995; 10 (5): 610–1.
23. Avakian SD, Annicchino-Bizzacchi JM, Grinberg M et al. Apolipoproteins AI, B, and E polymorphisms in severe aortic valve stenosis. Clin Genet 2001; 60: 381–4.
24. Awan Z, Alrasadi K, Francis GA et al. Vascular calcifications in homozygote familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2008; 28 (4): 777–85.
25. Bairati F, DeBiasi S. Presence of a smooth muscle system in aortic valve leaflets. Anatomy and Embryology 1981; 161 (3): 329–40.
26. Benton JA, Kern HB, Leinwand LA et al. Statins block calcific nodule formation of valvular interstitial cells by inhibiting alpha-smooth muscle actin expression. Arterioscler Thromb Vasc Biol 2009; 29 (11): 1950–7.
27. Beppu S, Suzuki S, Matsuda H et al. Rapidity of progression of aortic stenosis in patients with congenital bicuspid aortic valves. Am J Cardiol 1993; 71: 322–7.
28. Bergler-Klein J, Klaar U, Heger M et al. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation 2004; 109: 2303–8.
29. Bonow RO, Carabello B, de Leon AC Jr et al. ACC/AHA guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Valvular Heart Disease). J Am Coll Cardiol 1998; 32: 1486–588.
30. Boon A, Cheriex E, Lodder J et al. Cardiac valve calcification: characteristics of patients with calcification of the mitral annulus or aortic valve. Heart 1997; 78: 472.
31. Brener SJ, Duffy C, Thomas JD. Progression of aortic stenosis in 394 patients: relation to changes in myocardial and mitral valve dysfunction. J Am Coll Cardiol 1995; 25: 305–10.
32. Bulpitt CJ, Beckett NS, Cooke J. Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens 2003; 21 (12): 2409–17.
33. Cawley PJ, Otto CM. Prevention of calcific aortic valve stenosis-fact or fiction? Ann Med 2009; 41 (2): 100–8.
34. Chambers J. The left ventricle in aortic stenosis: evidence for the use of ACE inhibitors. Heart 2006; 92 (3): 420–3.
35. Chandra HR, Goldstein JA, Choudhary N et al. Adverse outcome in aortic sclerosis is associated with coronary artery disease and inflammation. J Am Coll Cardiol 2004; 43: 169–75.
36. Chizner MA, Pearle DL, de Leon AC Jr. The natural history of aortic stenosis in adults. Am Heart J 1980; 99 (4): 419–24.
37. Cosmi JE, Kort S, Tunick PA et al. The risk of the development of aortic stenosis in patients with «benign» aortic valve thickening. Arch Intern Med 2002; 162: 2345–7.
38. Davutoglu V, Yilmaz M, Soydinc S et al. Mitral annular calcification is associated with osteoporosis in women. Am Heart J 2004; 147: 1113–6.
39. Ekbom T, Linjer E, Hedner T et al. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP–Hypertension-2. Blood Press 2004; 13 (3): 137–41.
40. Elder DH, McAlpine-Scott V, Choy AM et al. Aortic valvular heart disease: Is there a place for angiotensin-converting-enzyme inhibitors? Expert Rev Cardiovasc Ther 2013; 11 (1): 107–14.
41. Faggiano P, Ghizzoni G, Sorgato A et al. Rate of progression of valvular aortic stenosis in adults. Am J Cardiol 1992; 70: 229–33.
42. Faggiano P, Aurigemma GP, Rusconi C. Progression of valvular AS in adults: literature review and clinical implication. Am Heart J 1996; 132: 408–17.
43. Faggiano P, Antonini-Canterin F. Progression of aortic valve sclerosis to aortic stenosis. Am J Cardiol 2003; 91: 99–101.
44. Fantus D, Awan Z, Seidah NG. Aortic calcification: Novel insights from familial hypercholesterolemia and potential role for the low-density lipoprotein receptor. Atherosclerosis 2013; 226 (1): 9–15.
45. Galante A, Pietroiusti A, Vellini M et al. C-reactive protein is increased in patients with degenerative aortic valvular stenosis. J Am Coll Cardiol 2001; 38: 1078–82.
46. Ge H, Zhang Q, Wang BY. Therapeutic effect of statin on aortic stenosis: a review with meta-analysis. J Clin Pharm Ther 2010; 35 (4): 385–93.
47. Gerber IL, Stewart RA, Legget ME et al. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation 2003; 107: 1884–90.
48. Ghaisas NK, Foley JB, O’Briain DS et al. Adhesion molecules in nonrheumatic aortic valve disease: endothelial expression, serum levels and effects of valve replacement. J Am Coll Cardiol 2000; 36: 2257–62.
49. Goldstein RE. Bone modifiers and the quest to slow progression of aortic stenosis. Am J Cardiol 2009; 1 (104) [1]: 125–7.
50. Gonçalves G, Zornoff LA, Ribeiro HB et al. Blockade of renin-angiotensin system attenuates cardiac remodeling in rats undergoing aortic stenosis. Arq Bras Cardiol 2005; 84 (4): 304–8.
51. Gonzales ALF, Montero JA, Monzonis AM et al. Osseous metaplasia and hematopoietic bone marrow in a calcified aortic valve. Tex Heart Inst J 1997; 24 (3): 232.
52. Gössl M, Khosla S, Zhang X et al. Role of circulating osteogenic progenitor cells in calcific aortic stenosis. J Am Coll Cardiol 2012; 6 (60) [19]: 1945–53.
53. Grau JB, Poggio P, Sainger R et al. Analysis of osteopontin levels for the identification of asymptomatic patients with calcific aortic valve disease. Ann Thorac Surg 2012; 93: 79–86.
54. Hermans H, Herijgers P, Holvoet P et al. Statins for calcific aortic valve stenosis: into oblivion after SALTIRE and SEAS? An extensive review from bench to bedside. Curr Probl Cardiol 2010; 35 (6): 284–306.
55. Horstkotte D, Loogen F. The natural history of aortic valve stenosis. Eur Heart J 1988; 9 (Suppl. E): 57–64.
56. Ikeda T, Matsuda K, Itoh H et al. Plasma levels of brain and atrial natriuretic peptides elevate in proportion to left ventricular end-systolic wall stress in patients with aortic stenosis. Am Heart J 1997; 133: 307–14.
57. Jian B, Jones PL, Li Q et al. Matrix metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosis. Am J Pathol 2001; 159: 321–7.
58. Jian B, Narula N, Li QY et al. Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Ann Thorac Surg 2003; 75: 457–65.
59. Jiménez-Candil J, Bermejo J, Yotti R et al. Effects of angiotensin converting enzyme inhibitors in hypertensive patients with aortic valve stenosis: a drug withdrawal study. Heart 2005; 91 (10): 1311–8.
60. John AS, Dill T, Brandt RR et al. Magnetic resonance to assess the aortic valve area in aortic stenosis: how does it compare to current diagnostic standards? J Am Coll Cardiol 2003; 42: 519–26.
61. Kaden JJ, Dempfle CE, Grobholz R et al. Interleukin-1 beta promotes matrix metalloproteinase expression and cell proliferation in calcific aortic valve stenosis. Atherosclerosis 2003; 170: 205–11.
62. Kelly TA, Rothbart RM, Cooper CM et al. Comparison of outcome of asymptomatic to symptomatic patients older than 20 years of age with valvular aortic stenosis. Am J Cardiol 1988; 61: 123–30.
63. Kochar MS, Bolek G, Kalbfleisch JH. A 52-week comparison of lisinopril, hydrochlorothiazide, and their combination in hypertension. J Clin Pharmacol 1987; 27: 373–7.
64. Leduc JJ, Madonna O, Gressin V. Evaluation of lisinopril and lisinopril–hydrochlorothiazide combination in mild to moderate arterial hypertension. Therapie 1994; 49 (1): 17–22.
65. Lee YS, Chou YY. Endothelial alterations and senile calcific aortic stenosis: an electron microscopic observation. Proc Natl Sci (Counc Repub China) Part B 1997; 21: 137–43.
66. Lindroos M, Tilvis R, Heikkilä J. Calcific degeneration of the aortic valve in old age: is the development of flow obstruction predictable? J Intern Med 1996; 239: 269–73.
67. Lindroos M, Kupari M, Heikkila J. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol 1993; 21: 1220–5.
68. Lindroos M, Kupari M, Valvanne J et al. Factors associated with calcific aortic valve degeneration in the elderly. Eur Heart J 1994; 15: 865–70.
69. Mehta J, Lopez LM, Thorman AD. Lisinopril versus lisinopril plus hydrochlorothiazide in essential hypertension. Am J Cardiol 1988; 61 (10): 803–6.
70. Messika-Zeitoun D, Aubry MC, Detaint D et al. Evaluation and clinical implications of aortic valve calcification measured by electron-beam computed tomography. Circulation 2004; 110: 356–62.
71. Miller E. Introduction to lisinopril–hydrochlorothiazide combination. J Hum Hypertens 1991; 5: 49–51.
72. Miller JD, Weiss RM, Heistad DD. Calcific aortic valve stenosis: methods, models, and mechanisms. Circ Res 2011; 27 (108) [11]: 1392–412.
73. Mohler ER, Sheridan MJ, Nichols R et al. Development and progression of aortic valve stenosis: atherosclerosis risk factors – a causal relationship? A clinical morphologic study. Clin Cardiol 1991; 14: 995–9.
74. Mohler ER, Gannon F, Reynolds C et al. Bone formation and inflammation in cardiac valves. Circulation 2001; 103: 1522–8.
75. Mönckeberg JG. Der normale histologische Bau und die Sklerose Aortenklappen. Virchows Archiv fur pathologische Anatomie und Physiology und fur Klinische Medizin 1904; Bd. 176: S472–96.
76. Nadir MA, Wei L, Elder DH et al. Impact of renin-angiotensin system blockade therapy on outcome in aortic stenosis. J Am Coll Cardiol 2011; 2 (58) [6]: 570–6.
77. Ngo DT, Stafford I, Sverdlov AL. Ramipril retards development of aortic valve stenosis in a rabbit model: mechanistic considerations. Br J Pharmacol 2011; 162 (3): 722–32.
78. Novaro GM, Sachar R, Pearce GL et al. Association between apolipoprotein E alleles and calcific valvular heart disease. Circulation 2003; 108: 1804–8.
79. Novaro GM, Aronow HD, Mayer-Sabik E. Plasma homocysteine and calcific aortic valve disease. Heart 2004; 90: 802–3.
80. O’Brien KD, Reichenbach DD, Marcovina SM et al. Apolipoproteins B, (a) and E accumulate in the morphologically early lesion of «degenerative» valvular aortic stenosis. Arterioscler Thromb Vasc Biol 1996; 16: 523–32.
81. O’Brien KD, Shavelle DM, Caulfield MT et al. Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation 2002; 106: 2224–30.
82. Olsen MH, Wachtell K, Bella JN et al. Aortic valve sclerosis relates to cardiovascular events in patients with hypertension (a LIFE substudy). Am J Cardiol 2005; 95: 132–6.
83. Olsson M, Dalsgaard CJ, Haegerstrand A et al. Accumulation of T lymphocytes and expression of interleukin-2 receptors in nonrheumatic stenotic aortic valves. J Am Coll Cardiol 1994; 23: 1162–70.
84. Olsson M, Thyberg J, Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol 1999; 19: 1218–22.
85. Ortlepp JR, Schmitz F, Mevissen V et al. The amount of calcium-deficient hexagonal hydroxyapatite in aortic valves is influenced by gender and associated with genetic polymorphisms in patients with severe calcific aortic stenosis. Eur Heart J 2004; 25 (6): 514–22.
86. Otto CM, Pearlman AS, Gardner CL. Hemodynamic progression of aortic stenosis in adults assessed by Doppler echocardiography. J Am Coll Cardiol 1989; 13: 545–50.
87. Otto CM, Kuusisto J, Reichenbach DD et al. Characterization of the early lesion in «degenerative» valvular aortic stenosis: histological and immunohistochemical studies. Circulation 1994; 90: 844–53.
88. Otto CM, Burwash IG, Legget ME et al. Prospective study of asymptomatic valvular aortic stenosis: clinical, echocardiographic, and exercise predictors of outcome. Circulation 1997; 95: 2262–70.
89. Otto CM, Lind BK, Kitzman DW et al. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 1999; 341: 142–7.
90. Otto CM. Calcific aortic valve disease: new concepts. Semin Thorac Cardiovasc Surg 2010; 22: 276–84.
91. Pachulski RT, Chan KL. Progression of aortic valve dysfunction in 51 adult patients with congenital bicuspid aortic valve: assessment and follow-up by Doppler echocardiography. Br Heart J 1993; 69: 237–40.
92. Parolari A, Tremoli E, Cavallotti L. Do statins improve outcomes and delay the progression of non-rheumatic calcific aortic stenosis? Heart 2011; 97 (7): 523–9.
93. Pellikka PA, Nishimura RA, Bailey KR. The natural history of adults with asymptomatic, hemodynamically significant aortic stenosis. J Am Coll Cardiol 1990; 15: 1012–7.
94. Peltier M, Trojette F, Sarano ME et al. Relation between cardiovascular risk factors and nonrheumatic severe calcific aortic stenosis among patients with a three-cuspid aortic valve. Am J Cardiol 2003; 91: 97–9.
95. Perrotta I, Russo E, Camastra C et al. New evidence for a critical role of elastin in calcification of native heart valves: immunohistochemical and ultrastructural study with literature review. Histopathology 2011; 59: 504–13.
96. Poggianti E, Venneri L, Chubuchny V et al. Aortic valve sclerosis is associated with systemic endothelial dysfunction. J Am Coll Cardiol 2003; 41: 136–41.
97. Qi W, Mathisen P, Kjekshus J et al. Natriuretic peptides in patients with aortic stenosis. Am Heart J 2001; 142: 725–32.
98. Rafeiyian S, Mojtahedzadeh S, Hekmat M et al. Supravalvular and valvular aortic stenosis in heterozygous familial hypercholesterolemia. Med Princ Pract 2007; 16 (4): 315–7.
99. Rajamannan NM, Subramaniam M, Rickard D et al. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 2003; 6 (107) [17]: 2181–4.
100. Rajamannan NM. Bicuspid aortic valve disease: the role of oxidative stress in Lrp5 bone formation. Cardiovasc Pathol 2011; 20 (3): 168–76.
101. Reisin E, Weir MR, Falkner B еt al. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. Hypertension 1997; 30: 140–5.
102. Roger VL, Tajik AJ, Bailey KR et al. Progression of aortic stenosis in adults: new appraisal using Doppler echocardiography. Am Heart J 1990; 119: 331–8.
103. Rosenhek R, Binder T, Porenta G et al. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med 2000; 343: 611–7.
104. Satta J, Melkko J, Pollanen R et al. Progression of human aortic valve stenosis is associated with tenascin-C expression. J Am Coll Cardiol 2002; 39: 96–101.
105. Stewart BF, Siscovick D, Lind BK et al. Clinical factors associated with calcific aortic valve disease: Cardiovascular Health Study. J Am Coll Cardiol 1997; 29: 630–4.
106. Strickberger SA, Schulman SP, Hutchins GM. Association of Paget’s disease of bone with calcific aortic valve disease. Am J Med 1987; 82: 953–6.
107. Sugihara N, Matsuzaki M. The influence of severe bone loss on mitral annular calcification in postmenopausal osteoporosis of elderly Japanese women. Jpn Circ J 1993; 57: 14–26.
108. Thiago L, Tsuj SR, Atallah AN et al. Statins for progression of aortic valve stenosis and the best evidence for making decisions in health care. Sao Paulo Med J 2011; 6 (129) [1]: 41–5.
109. Turina J, Hess O, Sepulcri F et al. Spontaneous course of aortic valve disease. Eur Heart J 1987; 8: 471–83.
110. Urena P, Malergue MC, Goldfarb B et al. Evolutive aortic stenosis in hemodialysis patients: analysis of risk factors. Nephrologie 1999; 20: 217–25.
111. Wallby L, Janerot-Sjoberg B, Steffensen T et al. T lymphocyte infiltration in non-rheumatic aortic stenosis: a comparative descriptive study between tricuspid and bicuspid aortic valves. Heart 2002; 88: 348–51.

И.В.Егоров
Институт повышения квалификации и переподготовки кадров ФГБОУ ВПО РУДН